Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.29), $0.14 worse than the analyst estimate of ($1.15). Revenue for the quarter came in at $207 million versus the consensus estimate of $192.15 million.

GUIDANCE:

Ultragenyx Pharma sees FY2026 revenue of $730-760 million, versus the consensus of $790.7 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.